PVG Asset Management announced its plan for the first 100 days at Anavex Life Sciences Corp. (AVXL). PVG Asset Management's 100-day plan announcement may moderately affect Anavex's operations and market sentiment.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2024 | ‡‡‡ |
|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 151.02 | 132.19 | 102.58 | 118.33 |
| Receivables | 2.71 | 2.45 | 0.81 | 1.00 |
| Inventory | — | — | — | — |
| Other | 0.65 | — | — | — |
| 154.39 | 135.57 | 103.82 | 120.14 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 4.32 | 9.63 | 4.25 | 3.66 |
| ST’ Debt | — | — | — | — |
| Other | 8.21 | — | — | — |
| 12.53 | 15.30 | 8.95 | 7.69 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Year |
|---|
| Dec | Mar | Jun | Sep | Year | |
|---|---|---|---|---|---|
| ’26 | (7.15) | (4.44) | (9.10) | — |
—
|
| ’25 | (12.12) | (5.86) | (12.46) | (8.60) |
(39.04)
|
| ’24 | (7.32) | (11.66) | (5.18) | (6.66) |
(30.81)
|
| ’23 | (5.79) | (8.49) | (7.65) | (5.85) |
(27.78)
|
| ’22 | (3.50) | (9.64) | (7.05) | (4.04) |
(24.24)
|
| ’21 | (7.87) | (7.32) | (7.52) | (7.67) |
(30.38)
|
| ’20 | (5.73) | (5.26) | (4.04) | (6.25) |
(21.29)
|
| Dec | Mar | Jun | Sep | Year | |
|---|---|---|---|---|---|
| ’26 | (7.15) | (4.44) | (9.10) | — |
—
|
| ’25 | (12.12) | (5.86) | (12.46) | (8.60) |
(39.04)
|
| ’24 | (7.32) | (11.66) | (5.18) | (6.66) |
(30.81)
|
| ’23 | (5.79) | (8.49) | (7.65) | (5.85) |
(27.78)
|
| ’22 | (3.50) | (9.64) | (7.05) | (4.04) |
(24.24)
|
| ’21 | (7.87) | (7.32) | (7.52) | (7.67) |
(30.38)
|
| ’20 | (5.73) | (5.26) | (4.04) | (6.25) |
(21.29)
|
| Dec | Mar | Jun | Sep | Year | |
|---|---|---|---|---|---|
| ’26 | (0.06) | (0.06) | 0.08 | — |
—
|
| ’25 | (0.14) | (0.13) | (0.16) | (0.11) |
(0.54)
|
| ’24 | (0.11) | (0.13) | (0.14) | (0.14) |
(0.52)
|
| ’23 | (0.17) | (0.17) | (0.14) | (0.12) |
(0.60)
|
| ’22 | (0.14) | (0.14) | (0.16) | (0.18) |
(0.62)
|
| ’21 | (0.12) | (0.12) | (0.14) | (0.15) |
(0.54)
|
| ’20 | (0.12) | (0.12) | (0.11) | (0.10) |
(0.45)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | 7.13 | 4.90 | 3.25 | 2.86 | — | — | — |
Low Price
|
| ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 18.19 | 11.93 | 14.44 | 14.25 | — | — | — |
High Price
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 38 | 40 | 42 | 34 | — | — | — |
Employees
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| ‡‡‡ | — | — | — | — | — | — | — | — | — | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (47.62) | (47.50) | (43.00) | (46.38) | — | — | — |
EBT
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (47.98) | (47.50) | (43.00) | (46.38) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| ‡‡‡‡‡ | — | — | ‡‡‡‡‡ | — | — | — | — | — | — | — | — | — |
Depreciation
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.62) | (0.60) | (0.52) | (0.54) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.32) | (0.35) | (0.37) | (0.46) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.32) | (0.35) | (0.37) | (0.46) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.85 | 1.78 | 1.44 | 1.11 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 76.91 | 79.79 | 83.47 | 85.29 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ |
PE Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (24.24) | (27.78) | (30.81) | (39.04) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (24.24) | (27.78) | (30.81) | (39.04) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 142.49 | 141.85 | 120.26 | 94.87 | — | — | — |
Working Cap'
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (149.16) | (151.02) | (132.19) | (102.58) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 142.49 | 141.85 | 120.26 | 94.87 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (30.53%) | (30.94%) | (29.66%) | (38.75%) | — | — | — |
ROA
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (32.71%) | (33.41%) | (32.81%) | (43.11%) | — | — | — |
ROE
|
Anavex Life Sciences (AVXL), a clinical-stage biotech targeting neurological disorders like Alzheimer’s, Rett syndrome, and Parkinson’s, exemplifies the high-stakes world of pre-revenue drug development. With zero revenue since 2016, the company has endured escalating cash burn—net losses peaking at $48 million in 2022 before stabilizing around $43-46 million—and 143% share dilution to fund trials. Yet, a robust $103 million net cash position provides runway, while the stock’s plunge to multi-year lows (down 78% from 2021 highs) reflects trial delays rather than fundamentals, decoupling price from persistent negative ROE and cash flows.
Analyst forecasts paint a transformative picture: Revenue ignites at $36.5 million in 2025-2026, surging 853% to $349 million in 2027 alongside a $217 million profit swing and EPS flipping to +$2.27. Price targets imply 410-510% upside, betting on blarcamesine approvals from ongoing Phase 3 trials in Rett and Alzheimer’s, potentially unlocking blockbuster sales.
This setup screams opportunity for risk-tolerant investors—oversold shares near dreams of commercialization—but trial flops (80%+ Phase 3 failure rate), competition from Eli Lilly’s Kisunla, and dilution risks loom large. Dive into the full analysis for the catalysts, correlations, and numbers that could make AVXL’s slump a legendary dip or another biotech bust.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.